

SUPPLEMENTAL MATERIAL

Table S1. Characteristics of the 116 patients with atrial fibrillation and the 18 patients with atrial flutter.

Patient's characteristics	<i>AF patients</i>		<i>Atrial flutter patients</i>	
	PB waveform	BTE waveform	PB waveform	BTE waveform
<i>Demographics</i>				
No. of patients	60	56	9	9
Age, years (mean \pm SD)	66 \pm 9	66 \pm 9	68 \pm 11	70 \pm 5
Male sex (%)	43 (72)	42 (75)	8 (89)	9 (100)
Atrial flutter	-	-	-	-
AF or -flutter duration in months, median (quartiles)	3 (2; 9)	5 (2; 23)	3 (2; 7)	8 (3; 44)
Prior cardioversions, median (quartiles)	0 (0; 0.25)	0 (0; 1)	0 (0; 0)	1 (0; 3)
Prior ablation, median (quartiles)	0 (0; 0)	0 (0; 0)	0 (0; 0)	0 (0; 1)
<i>Comorbidities, %</i>				
Hypertension	46 (77)	45 (80)	5 (56)	6 (67)
Congestive heart failure	18 (30)	10 (18)	2 (22)	2 (22)
Valvular heart disease	2 (3)	6 (11)	1 (11)	1 (11)
Thyroid disease	0 (0)	2 (4)	0 (0)	0 (0)
Prior stroke/transient ischemic attack	6 (10)	4 (7)	0 (0)	0 (0)
Prior myocardial infarction	1 (2)	5 (9)	0 (0)	0 (0)
Ischemic heart disease	12 (20)	12 (21)	1 (11)	0 (0)
Hyperlipidemia	25 (42)	26 (46)	4 (44)	2 (22)
Chronic obstructive pulmonary disease	2 (3)	4 (7)	0 (0)	1 (11)

Cardiac medication, %

Amiodarone	6 (10)	14 (25)	0 (0)	4 (44)
Digoxin	13 (22)	17 (30)	1 (11)	1 (11)
Flecainide	1 (2)	1 (2)	0 (0)	0 (0)
ACE/Angiotensin-II blocker	41 (68)	36 (64)	3 (33)	4 (44)
Beta blocker	49 (82)	46 (82)	8 (89)	7 (78)
Calcium antagonist	16 (26)	18 (32)	0 (0)	2 (22)

Vital parameters and laboratory data

Body mass index, kg/m ²	29 ±6	31 ±5	28 ±5	28 ±7
Systolic blood pressure, mmHg	136 ±17	136 ±22	132 ±22	133 ±17
Diastolic blood pressure, mmHg	82 ±14	80 ±13	77 ±13	78 ±12
Heart rate before cardioversion, min ⁻¹	80 ±18	81 ±18	76 ±18	74 ±18
Estimated glomerular filtration rate	69 ±14	69 ±18	68 ±16	66 ±15
Hemoglobin (mmol/L)	9.3 ±0.8	9.4 ±0.9	8.9 ±0.7	8.9 ±1.0
Thyroid-stimulating hormone (IU x10 ⁻³ /L)	1.47 (1.00; 2.45)	1.67 (0.92;2.64)	1.70 (1.37; 2.59)	1.52 (1.19; 2.22)
Total propofol dose (mg)	116 ±44	108 ±35	89 ±26	96 ±14

Patient's symptoms (EHRA Score), %

I	27 (45)	22 (39)	4 (44)	4 (44)
II	28 (47)	24 (43)	3 (33)	5 (56)
III	5 (8)	10 (18)	2 (22)	0 (0)
IV	0 (0)	0 (0)	0 (0)	0 (0)

Abbreviations: PB; Pulsed biphasic, BTE; Biphasic truncated exponential, AF; Atrial fibrillation, ACE;

Angiotensin converting enzyme, EHRA; European Heart Rhythm Association score of AF-related symptoms.

Table S2. Characteristics of the 24 patients receiving amiodarone treatment and the 110 patients not receiving amiodarone.

Patient's characteristics	<i>Receiving amiodarone</i>		<i>Not receiving amiodarone</i>	
	PB waveform	BTE waveform	PB waveform	BTE waveform
<i>Demographics</i>				
No. of patients	6	18	63	47
Age, years (mean \pm SD)	59 \pm 10	66 \pm 9	67 \pm 9	67 \pm 8
Male sex (%)	5 (83)	16 (89)	46 (73)	35 (75)
Atrial flutter	9 (13)	9 (14)	9 (13)	9 (14)
AF or –flutter duration in months, median (quartiles)	11 (9; 18)	22 (5; 37)	3 (2; 7)	4 (2; 17)
Prior cardioversions, median (quartiles)	1 (1; 1.75)	2 (0.25; 3)	0 (0; 0)	0 (0; 0)
Prior pulmonary vein ablation, median (quartiles)	0 (0; 0)	0 (0; 1)	0 (0; 0)	0 (0; 0)
<i>Comorbidities, %</i>				
Hypertension	0 (0)	14 (78)	45 (71)	37 (79)
Congestive heart failure	3 (50)	4 (22)	7 (27)	8 (17)
Valvular heart disease	0 (0)	3 (17)	3 (5)	4 (9)
Thyroid disease	0 (0)	1 (6)	0 (0)	1 (2)
Prior stroke/transient ischemic attack	0 (0)	0 (0)	6 (10)	4 (8)
Prior myocardial infarction	0 (0)	1 (6)	1 (2)	4 (9)
Ischemic heart disease	2 (33)	3 (17)	11 (17)	9 (19)
Hyperlipidemia	2 (33)	7 (39)	27 (43)	21 (45)
Chronic obstructive pulmonary disease	0 (0)	1 (6)	2 (3)	4 (9)

Cardiac medication, %

Amiodarone	-	-	-	-
Digoxin	0 (0)	4 (22)	14 (22)	14 (30)
Flecainide	0 (0)	1 (6)	1 (2)	0 (0)
ACE/Angiotensin-II blockers	6 (100)	10 (55)	38 (60)	30 (64)
Beta blockers	4 (67)	11 (61)	53 (84)	42 (89)
Calcium channel blockers	3 (50)	4 (22)	13 (21)	16 (34)

Vital parameters and laboratory data

Body mass index, kg/m ²	31 ±5	29 ±4	29 ±6	30 ±6
Systolic blood pressure, mmHg	145 ±15	130 ±22	135 ±18	137 ±21
Diastolic blood pressure, mmHg	91 ±11	80 ±14	81 ±14	79 ±13
Heart rate before cardioversion, min ⁻¹	86 ±27	85 ±25	80 ±20	79 ±14
Estimated glomerular filtration rate	71 ±17	64 ±19	69 ±14	70 ±16
Hemoglobin (mmol/L)	9.3 ±0.9	9.2 ±0.9	9.3 ±0.8	9.3 ±0.9
Thyroid-stimulating hormone (IU x10 ⁻³ /L)	3.00 (2.18; 3.69)	1.65 (1.08;2.70)	1.47 (0.99; 2.30)	1.67 (0.94; 2.44)
Total propofol dose (mg)	125 ±30	103 ±30	112 ±43	108 ±30

Patient's symptoms (EHRA Score), %

I	3 (50)	5 (28)	28 (44)	21 (45)
II	3 (50)	10 (56)	28 (44)	19 (41)
III	0 (0)	3 (17)	7 (11)	7 (15)
IV	0 (0)	0 (0)	0 (0)	0 (0)

Abbreviations: PB; Pulsed biphasic, BTE; Biphasic truncated exponential, AF; Atrial fibrillation, ACE;

Angiotensin converting enzyme, EHRA; European Heart Rhythm Association score of AF-related symptoms.